Regencell Bioscience (NASDAQ:RGC) Trading Down 6.3% – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares fell 6.3% on Monday . The company traded as low as $5.50 and last traded at $5.5070. Approximately 74,501 shares were traded during trading, a decline of 77% from the average session volume of 323,320 shares. The stock had previously closed at $5.88.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The business has a 50 day moving average of $18.64 and a 200 day moving average of $24.79.

Regencell Bioscience (NASDAQ:RGC) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.00) EPS for the quarter.

Institutional Trading of Regencell Bioscience

A number of institutional investors and hedge funds have recently modified their holdings of RGC. Squarepoint Ops LLC acquired a new stake in shares of Regencell Bioscience in the 2nd quarter valued at approximately $1,701,000. BNP Paribas Financial Markets bought a new position in Regencell Bioscience during the 2nd quarter worth approximately $768,000. XTX Topco Ltd acquired a new position in Regencell Bioscience during the third quarter valued at approximately $598,000. Vident Advisory LLC grew its holdings in Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the period. Finally, Bank of America Corp DE increased its stake in Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares in the last quarter. 0.13% of the stock is owned by institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.